Lynx1 Capital Management LP Gh Research PLC Transaction History

Lynx1 Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$10.5 - $14.81 $41.7 Million - $58.7 Million	3,966,726 New	3,966,726 $46.3 Million
Q1 2024 May 15, 2024	BUY	$5.34 - $11.09 $7.86 Million - $16.3 Million	1,471,946 Added 80.06%	3,310,563 $35.3 Million
Q4 2023 Feb 14, 2024	BUY	$5.26 - $11.04 $3.87 Million - $8.12 Million	735,439 Added 66.67%	1,838,617 $10.7 Million
Q3 2023 Nov 14, 2023	BUY	$9.8 - $14.15 $1.31 Million - $1.89 Million	133,804 Added 13.8%	1,103,178 $11.1 Million
Q2 2023 Aug 14, 2023	BUY	$7.88 - $12.74 $7.64 Million - $12.3 Million	969,374 New	969,374 $11.5 Million

23.5M

63.1K

1.9K

Ticker GHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,020,800
Market Cap $340M
Description
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH0...

Get notified when there are updates to the investment portfolio of Lynx1 Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Lynx1 Capital Management LP with notifications on news.